Longeveron is currently enrolling subjects in its Phase 2b multi-center clinical trial designed to test the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) for the treatment of subjects with clinically diagnosed with Aging Frailty. This is the only known trial in the world underway to use MSCs to treat Aging Frailty. Frailty is a common aging-related medical syndrome with multiple causes and contributors, characterized by diminished strength, endurance, and reduced physiologic function. Frail individuals have an increased risk of poor clinical outcomes such as hospitalization, dependency, disability and/or death. Signs and symptoms of frailty include reduced activity, slowness, involuntary weight loss, weakness, and fatigue. Additionally, there is a connection between frailty and chronic inflammation in the body.
Frail elderly patients place significant demand for healthcare services and there are no approved therapeutics for the syndrome. Longeveron was awarded a competitive grants from the National Institutes of Health in the amount of $1.15 million to conduct this trial and also study the Metabolic Syndrome which is closely associated with Aging Frailty.
